Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Relatlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Relatlimab in Solid Tumor

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Relatlimab overview

Relatlimab (BMS-986016) is under development for the treatment of hematological malignancies, renal medullary carcinoma (RMC), newly diagnosed older acute myeloid leukemia, metastatic hepatocellular carcinoma (HCC), advanced unresectable or metastatic basal cell carcinoma, relapsed and refractory acute myeloid leukemia, non-Hodgkin lymphoma, relapsed refractory multiple myeloma, Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia (CLL), melanoma, metastatic uveal melanoma, multiple myeloma, gastric cancer, soft tissue sarcoma recurrent head and neck squamous cell carcinoma, non-small cell lung cancer, cervical cancer, ovarian cancer, bladder cancer, renal cell carcinoma, hepatocellular cancer, recurrent glioblastoma multiforme, gliosarcoma, colorectal cancer (solid tumors) and metastatic or unresectable melanoma (first line therapy). It is administered intravenously. It is a monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities.
It was under development for solid tumors in Japan.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.

For a complete picture of Relatlimab’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.